Navigation Links
Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
Date:9/24/2007

Longer Term Growth of Diabetic Neuropathy Market Will Be Driven by Launches of Disease-Modifying Therapies, According to a New Report from Decision

Resources

WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.

The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.

Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.

"The diabetic neuropathy market will experience growth during the second half of our study period because of increasing use of Pfizer's antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approved specifically for the treatment of diabetic neuropathic pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term growth will also be driven by the launch of novel disease-modifying therapies such as Dainippon/Eisai/Kyorin's ranirestat and Sangamo Biosciences' SB-509."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approval For Lucentis
2. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
3. Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
4. Sleepy drivers increase road death toll
5. Traffic Violations Result in Safer Drivers
6. Dyslexia may slow a drivers reaction time as much as moderate drinking!!
7. Study suggests symptom driven therapy for adults with asthma
8. Peppermint or cinnamon smell can make drivers more alert
9. Mechanical forces drive early heart development
10. Measles Vaccination Drive Intensified In Quake-Hit Pakistan
11. More Funds Are Required For Immunisation Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Casa Velas, an adults-only boutique ... precious stones to complement its new wellness suites . The two 1,350 sq. ... a plethora of special services and insuite amenities, from a custom soap selection and ...
(Date:5/25/2016)... ... 25, 2016 , ... Laser Skin & Wellness Center is excited ... time of female aging. The Juliet™ procedure helps to reverse the ... leakage, laxity, itchiness and pain have reported real relief from these and other problems ...
(Date:5/25/2016)... TX (PRWEB) , ... May 25, 2016 , ... ... the United States, named Dr. Anh Tat Nguyen, as the Medical Director of its ... the facility Medical Director of our new DeSoto location,” said Dr. James M. Muzzarelli, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is launching a Kickstarter campaign ... hanging wipe dispenser. The campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco ... The goal is to raise $1,000 per day for a total of $25,000. The ...
(Date:5/24/2016)... ... May 24, 2016 , ... Women's Excellence ... Roberta Jordan is a Certified Nurse Midwife who was born and raised in ... went on to complete her masters degree from the University of Mexico. Roberta ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... STAMFORD, Conn. , May 23, 2016 /PRNewswire/ ... Company has entered into an agreement with Egalet ... various patent claims. As part of the agreement ... rights, and will enable all three companies to ... abuse-deterrent properties. "This agreement reflects the ...
(Date:5/20/2016)... India , May 20, 2016 ... Survey Report 2016 to Medical Devices of its ... and in-depth survey on the current state of ... overview of the industry like definitions, classifications, Specifications, ... information about manufacturing process like Raw Material Suppliers, ...
(Date:5/20/2016)... , May 20, 2016 ... Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation ... Biological Drugs - This New Study Reveals Selling ... Ahead ,What is the future ... the latest technological and commercial analysis. Staying ahead ...
Breaking Medicine Technology: